Northwestern Scientists Repair and Reverse ALS Neuron Damage in Lab Using New Non-Toxic Compound

In a study using a non-toxic substance on mice, Northwestern University researchers have identified the first compound that eliminates the ongoing degeneration of brain neurons in the paralyzing disease known as ALS.

Researchers Hande Ozdinler and Richard Silverman -Northwestern

Amyotrophic lateral sclerosis is a neurodegenerative disease in which upper motor neurons degrade in victims, producing a swift and fatal demise.

In addition to ALS, other motor neuron diseases, such as hereditary spastic paraplegia (HSP) and primary lateral sclerosis (PLS) progress in a similar fashion.

In ALS, movement-initiating nerve cells in the brain (upper motor neurons) and muscle-controlling nerve cells in the spinal cord (lower motor neurons) die—and, so far, there has been no drug or treatment for the brain component of ALS, and no drug for HSP and PLS patients.

“Even though the upper motor neurons are responsible for the initiation and modulation of movement, and their degeneration is an early event in ALS, so far there has been no treatment option to improve their health,” said senior author Hande Ozdinler, associate professor of neurology at Northwestern University Feinberg School of Medicine.

“We have identified the first compound that improves the health of upper motor neurons that become diseased.”

RELATED: Yale Scientists Successfully Repair Injured Spinal Cords Using Patients’ Own Stem Cells

Ozdinler collaborated with study author Richard B. Silverman, a Northwestern chemistry professor, and published the results in Clinical and Translational Medicine last month on Feb. 23.

The study was initiated after Silverman identified a compound, NU-9, developed in his lab for its ability to reduce protein misfolding in critical cell lines. The compound is not toxic and crosses the blood brain barrier.

“I am very excited to find out if our hypothesis that stabilizing upper motor neurons in mice will translate to humans and NU-9 will provide hope for those inflicted with currently untreatable upper motor neuron diseases,” Silverman said.

POPULAR: Doctor Determines Perfect Prescriptions For Stage 4 Cancer: With Functional Profiling His Results Are ‘Stunning’

The NU-9 compound addresses two of the important factors that cause upper motor neurons to become diseased in ALS: protein misfolding and protein clumping inside the cell. Proteins fold in a unique way to function; when they misfold they become toxic to the neuron. Sometimes proteins aggregate inside the cell and cause pathology as in the TDP-43 protein pathology. This happens in about 90% of all ALS patient brains and is one of the most common problems in neurodegeneration.

The research team began to investigate whether NU-9 would be able to help repair upper motor neurons that become diseased due to increased protein misfolding in ALS. The results in mice were positive. Scientists next performed experiments to reveal how and why the diseased upper motor neurons regained their health.

Restoring neurons to robust health

After administering NU-9, both the mitochondria (the cell’s energy producer) and the endoplasmic reticulum (the cell’s protein producer) began to regain their health and integrity resulting in improved neuron health. The upper motor neurons were more intact, their cell bodies were larger and the dendrites were not riddled with holes.

CHECK OUT: Scientists Develop Ultra-Precise Lasers to Remove Cancers Without Damaging Healthy Tissue

They stopped degenerating so much that the diseased neurons became similar to healthy control neurons after 60 days of NU-9 treatment.

Commanders-in-chief of movement

Upper motor neurons are the brain’s commanders-in-chief of movement. They carry the brain’s input to spinal cord targets to initiate voluntary movement. The degeneration of these neurons impairs the connection from the brain to the spinal cord and leads to paralysis in patients.

Lower motor neurons have direct connections with the muscle, contracting muscle to execute movement. Thus, the lower motor neuron activity is in part controlled by the upper motor neurons.

Ozdinler and colleagues will now complete more detailed toxicology and pharmacokinetic studies prior to initiating a Phase 1 clinical trial.

(Source: Northwestern News Now)

MOVE This To Your Social Media Friends As Follow-up to Ice Bucket Challenge…

Leave a Comment